Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstrated a favorable safety profile with no serious adverse events related to treatment. The FDA has cleared the IND for a Phase 2 trial in adults with NF1-associated cNF, supporting further development of PAS-004 as a once-daily oral therapy. A webcast discussing the data will be available on November 13, 2026.
Pasithea Therapeutics' positive Phase 1/1b data for PAS-004 provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 13:11 WIB: out of 150 priced US health-sector stocks, 46 rose and 100 fell. Notable movers include CTXR at USD 0.54 with a 12.36% increase and 84% sell order activity, SANA at USD 2.06 down 10.04% with 60% buy orders, and BNGO at USD 1.00 down 9.09% with nearly balanced buy/sell activity and a typical hold time of 52 days.
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
The 9th Shandong-South Korea Economic and Trade Cooperation Conference and Yantai South Korea Week began on November 6 in Yantai, Shandong Province, highlighting strong economic ties between Shandong and South Korea. Over 150 enterprises participated...
Security firm 慢雾 warned that Pennysia's Settlement contract on Ethereum was exploited due to a flaw allowing arbitrary external calls. This flaw enabled attackers to transfer tokens that users had approved for the contract but not yet used, putting t...
An Ethereum wallet that originally acquired 38,800 ETH during the 2015 ICO sold 16,700 ETH in one transaction worth over $32.3 million. This sale represented about 43% of its original ICO allocation, which was purchased at just 31 cents per ETH. Howe...
Bitcoin's market dominance, currently around 61%, is crucial in deciding the near-term performance of altcoins. While Bitcoin gained 16.6% over the past 90 days, only 31 altcoins outperformed it, with a few like Bitway and Quant showing strong gains....
